Last $3.17 USD
Change Today +0.02 / 0.63%
Volume 60.1K
CYCC On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/13 - $5.25
52 Week Low
06/5/14 - $2.88
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/26/14
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $713.4K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $463.1K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $442.4K
Compensation as of Fiscal Year 2013.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Announces Presentation of Therapeutic Potential of CYC065, Second-Generation Cyclin Dependent Kinase Inhibitor

Cyclacel Pharmaceuticals, Inc. announced the presentation of preclinical data demonstrating the therapeutic potential of CYC065, the company's second-generation cyclin dependent kinase (CDK) inhibitor, to treat acute leukemias, and in particular those with rearrangements in the mixed lineage leukemia (MLL) gene. The data showed that in vitro all human acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cell lines with MLL rearrangements (MLLr) tested were sensitive to CYC065 and that the drug inhibited MLL-driven gene expression. Potent anticancer activity of CYC065 was demonstrated in vivo in AML xenograft models resulting in over 90% inhibition of tumor growth. The data were presented at the 2014 Society of Hematologic Oncology (SOHO) meeting taking place September 17-20, 2014 in Houston, Texas. The study (Poster no. 209) evaluated the anticancer activity of CYC065 in vitro assays of human AML and ALL cell lines with normal and mutated MLL gene status, CYC065's mechanism of action and determinants of cellular sensitivity. CYC065 induced rapid apoptosis and inhibited MLL-driven transcription of genes involved in leukemia stem cell biology. Cell line sensitivity correlated with the levels of proteins from the Bcl-2 family, which regulate apoptosis, and combining CYC065 with Bcl-2 inhibitors was synergistic in all tested leukemia lines. CYC065's potent anti-cancer activity was confirmed in AML xenograft models in which tumor growth inhibition ranging from 90% to 97% was achieved at well-tolerated dose levels.

Cyclacel Pharmaceuticals, Inc. Appoints Samuel L. Barker to the Board of Directors

Cyclacel Pharmaceuticals, Inc. announced the appointment of Samuel L. Barker to the Board of Directors. Dr. Barker has more than 40 years of experience in senior executive positions in the pharmaceutical industry where he played a significant role in the commercialization and success of several important pharmaceuticals including Taxol(R), Capoten(R), Glucophage(R) and Pravachol(R). His previous roles include co-founder of Clearview Projects, Inc., serving as its President and Chief Executive Officer from 2003 to 2004. Previously, Dr. Barker spent over 30 years at Bristol-Myers Squibb Company where he held positions in research and development, manufacturing, business development, sales and marketing, operations planning and general management. After the merger of Bristol-Myers and Squibb in 1989, he served as the President of Intercontinental Commercial Operations at Bristol-Myers Squibb Pharmaceutical Group. Dr. Barker currently serves on the Board of Directors of Lexicon Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2014

Cyclacel Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter ended June 30, 2014. For the quarter, the company announced total revenues of USD 356,000 compared to USD 264,000 for the same period a year ago. Operating loss was USD 5,575,000 compared to USD 4,154,000 for the same period a year ago. Loss from continuing operations before taxes was USD 5,635,000 compared to income from continuing operations before taxes of USD 1,248,000 for the same period a year ago. Net loss from continuing operations was USD 4,819,000 or USD 0.22 per basic and diluted share compared to net income from continuing operations of USD 1,478,000 or USD 0.10 per basic and diluted share for the same period a year ago. Net loss applicable to common shareholders was USD 4,862,000 or USD 0.22 per basic and diluted share compared to net income applicable to common shareholders of USD 1,429,000 or USD 0.10 per basic and diluted share for the same period a year ago. The revenue is related to previously awarded grants from the UK government being recognized over the period to progress CYC065, a Cyclin Dependent Kinase inhibitor, to IND and to complete IND-directed preclinical development of CYC140, a novel, orally available, Polo-Like Kinase 1 (PLK 1) inhibitor.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $3.17 USD +0.02

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.6x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at